DM Healthcare Investment

Convergence Biomanufacturing Ltd. launches world's first high-performance acoustic field bio-assembler

January 1, 2023

SHENZHEN, China, January 1, 2023 -- After nearly 1 year of R&D, design and manufacturing, the world's first high-performance acoustic field bio-assembler was officially launched. Based on the principle of reverse engineering biomimetic design, the ConvB Acoustic Field Bio-Assembler carries out precise manipulation of cells and biomaterials, mimics the cellular structure within human tissues, constructs ordered cell and extracellular matrix complexes, realizes effective cell-to-cell and cell-to-extracellular matrix contact communication, and remodels high simulation and functionalized tissues and organs in vitro.

Bio-manufacturing is an important part of the development strategy of China's biomedical industry and a hotspot at the forefront of research in the global biomedical field, and its industrialization in the fields of cell preparation, drug testing and clinical trials, functional organ substitution, and artificial meat shows a broad application prospect.

Traditional biomanufacturing is mainly to print out specific structures and tissue forms by mixing cells with bioink through extrusion, inkjet and other bio-3D printing technologies. However, there are certain technical bottlenecks in this type of technology, which can only print tissues and organs that are "similar in shape but not in spirit", and therefore are only applied to a few tissue constructs at present. Moreover, the low manufacturing efficiency of these technologies does not meet the demand for industrialized applications.

Convergence Biomanufacturing Ltd. has transformed the application of acoustic fields in biomanufacturing to create new solutions for the biomedical industry. The technology has multiple advantages in the field of tissue manufacturing, especially in cell assembly of stem cell origin: high throughput (simultaneous manufacturing of multiple samples), high efficiency (manufacturing efficiency in seconds), high connectivity (cells can be tightly connected to each other), and non-destructive (no cellular shear damage) to synchronously assemble a variety of cells to form a bionic, functionalized structure, and to achieve excellent biological effects. At the same time, the technology is highly scalable and compatible, and can be perfectly integrated with existing biofabrication technologies to accurately construct tissue mimics and biomimetic organs with biological effects close to those of the human body. In addition, this technology not only allows for the large-scale production of various artificial tissues and organs, but also provides an innovative technological platform for regenerative medicine clinical applications, drug research, artificial meat, cell production and preparation, and other industries.